63
Participants
Start Date
December 31, 2007
Primary Completion Date
March 31, 2013
Study Completion Date
June 30, 2015
SKI-606 (Bosutinib)
"Formulation: 100 mg Capsule for Part 1, 100 mg tablet for Part1 and Part 2.~SKI-606 (Bosutinib) will be taken by mouth with water and food as continuous once-daily dosing."
Kumamoto University Hospital, Kumamoto
Tohoku University Hospital, Sendai
National Cancer Center Hospital, Chuo-ku
Toyohashi Municipal Hospital, Aichi
Japanese Red Cross Nagoya First Hospital, Aichi
Aichi Cancer Center, Aichi
Akita University Hospital, Akita
Chiba University Hospital, Chiba
National Hospital Organization Kyushu Cancer Center, Fukuoka
Harasanshin Hospital, Fukuoka
Kobe City Medical Center General Hospital, Hyōgo
Hospital of Hyogo College of Medicine, Hyōgo
Kanazawa University Hospital, Ishikawa
Tokai University Hospital, Kanagawa
University Hospital,Kyoto Prefectural University of Medicine, Kyoto
Okayama University Hospital, Okayama
Osaka University Hospital, Osaka
Kinki University School of Medicine, Osaka
Saga University Hospital, Saga
Hamamatsu Medical Univ. HP Faculty of Medicine, Shizuoka
Tokyo Metropolitan Cancer&Infectious disease Ctr Komagome Hp, Tokyo
Japanese Red Cross Medical Center, Tokyo
Jikei University Hospital Daisan, Tokyo
Lead Sponsor
Pfizer
INDUSTRY